ArticleJournal of pain research2025
Risk Factors and Nomogram-Based Prediction of the Risk of Postherpetic Neuralgia in Patients with Herpes Zoster.
Article in Journal of pain research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Application of auricular therapy in postherpetic neuralgia: a scoping review.Frontiers in molecular neuroscience · 2026Pooled it
- Nomogram-Based Prediction Model for Postherpetic Neuralgia in Immunosuppressive Patients.Journal of clinical medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Postherpetic neuralgia (PHN) is considered as the most common complication of herpes zoster, and its incidence is increasing. The aim of this study was to explore the risk factors of postherpetic neuralgia (PHN) (ICD-10: B02.29) and to construct a predictive line graph model for early identification and prevention of PHN. Methods: In this study, we focused on a cohort of 650 patients who had been diagnosed with herpes zoster (HZ)(ICD-10: B02) and subsequently admitted to Wuhan Fourth Hospital over a span of seven years, specifically from January 2018 to June 2025. The study cohort was randomly divided into a training set (n=458) and a validation set (n=192), with an average age of 57.31±12.64 years in both groups. The Nomogram model, designed to predict the elevated risk of PHN in individuals with HZ was constructed through the R4.2.1 software "rms" package. The nomogram model's predictive performance was evaluated using the decision curve, while the calibration curve was utilized for internal validation. The model was also externally validated using a validation set of data. Results: The logistic regression analysis revealed that independent risk factors for PHN included age, the course of HZ, herpes in specific areas, VAS score, severity of skin damage, and temperature rising >1°C. The proposed Nomogram model, developed with the previously mentioned indicators, exhibits ROC curve area values of 0.943 for the training set and 0.900 for the validation set. The correction curve suggests that the model maintains high accuracy. Furthermore, the DCA outcomes reveal that the model possesses enhanced clinical utility at risk thresholds ranging from 0 to 0.99 for the training data and from 0.04 to 0.89 for the validation data. Conclusion: Our study confirms that age, the course of herpes zoster, herpes in special sites, VAS score, the severity of skin lesions, and a temperature increase of >1°C are independent risk factors for the occurrence of Postherpetic neuralgia (PHN). The nomogram model established based on these six indicators demonstrates good developmental potential and exhibits high discriminative predictive performance for Postherpetic neuralgia (PHN)in patients with herpes zoster.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.